Apollo Therapeutics Ltd
This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.
This study contains two parts: Part 1 and Part 2. Part 1 (24-Week Placebo-controlled Period): Eligible patients will be randomized in a 1:1:1:1 ratio to receive either camoteskimab dose 1, camoteskimab dose 2, camoteskimab dose 3 or placebo. Part 2 (Extension Period): In part 2, all participants will receive camoteskimab. This study will enroll both treatment-naive participants and those with an inadequate response to previous biologic therapy.
Inclusion Criteria: 1. Age 18-65 inclusive, at the time of signing the informed consent. 2. Chronic AD for at least 1 year based on clinically confirmed diagnosis of active AD, according to Hanfin and Rajka criteria. 3. Participants with moderate-to-severe AD defined by: 1. Investigator global assessment (IGA) score of ≥ 3 (on a scale of 0 to 4, in which three is moderate and four is severe) at Screening and Baseline. 2. AD involvement of ≥ 10% body surface area (BSA) at Screening and Baseline. 3. EASI score of ≥ 16 at Screening and at Baseline. 4. Peak pruritus numerical rating…
Drug Product
Inactive substance